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points (p = 0.007) lower pain score than non-duloxetine-treated patients among 
individuals who had any opioid use during the 12-month post-index period. CON-
CLUSIONS: Among similar VA patients with MDD, patients treated with duloxetine 
were associated with lower opioid use than those treated with other antidepressants. 
Among individuals with any opioid use over the 12-month post-index period, duloxetine-
treated patients had better pain scores than non-duloxetine-treated patients.
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OBJECTIVES: Although not approved for use in pediatrics, hydroxyurea has been 
shown to decrease painful vaso-occlusive events and hospitalizations (HU) in children 
with sickle cell disease (SCD), a genetic hematologic disorder primarily affecting 
people of African descent. However, few data exist on the use of HU, and adherence 
to treatment, in real-world settings. This study assessed the extent to which children 
with SCD are adherent with prescribed HU therapy and the association between HU 
adherence and economic outcomes in this population in a real-world setting. 
METHODS: Insurance claims of North Carolina Medicaid program enrollees (June 
1999-August 2008) were analyzed. Inclusion criteria were ≥1 claims with a diagnosis 
for SCD (i.e., ICD-9-CM 282.6, 282.6x), ≥2 HU prescriptions in the year following 
HU initiation, ≤18 years old at the time of HU initiation, and continuous Medicaid 
enrollment for ≥12 months prior to and following HU initiation. Adherence was 
measured using the medication possession ratio (MPR), with MPR > 0.8 considered 
adherent. Multivariable models were estimated to assess the association between HU 
adherence and economic outcomes (e.g., inpatient costs) in the ﬁ rst year of HU therapy. 
RESULTS: A totla of 159 subjects (55% female, mean age [SD] 11.3 [4.4] years) met all 
inclusion criteria. The mean MPR was 0.63, with 41% of subjects adherent. Multivariable 
models revealed that in the year following HU initiation, adherence was associated with 
a reduction in all-cause (-$3.695, p = 0.0003) and SCD-related (-$3.002, P < 0.0001) 
total, inpatient (-$2172, p = 0.001; -$1815, P < 0.0001, respectively), ER (-$314, P < 
0.0001; -$202, p = 0.002, respectively), outpatient (-$951, P < 0.0001; -$541, p = 0.005, 
respectively), and vaso-occlusive event-related (-$3639, P < 0.0001) costs, and an increase 
in all-cause (+$239, p = 0.014) and SCD-related pharmacy (+$198, P < 0.0001) costs. 
CONCLUSIONS: Adherence to HU among pediatric SCD patients may be suboptimal 
and improving adherence to HU therapy among these patients may reduce the eco-
nomic burden of the illness.
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OBJECTIVES: The aim of this study is to determine health care resource utilization 
and direct medical costs in patients treated with intravenous immunoglobulins (IVIGs) 
in Spain in 2009. METHODS: A cost-of-illness analyses was performed to estimate 
direct medical annual costs of patients treated with IVIGs. Prevalence data was 
obtained from the Spanish Primary Immunodeﬁ ciency registry. a semi-structured ques-
tionnaire was used to collect data on health care resource utilization and target popula-
tion distribution. Inpatient and outpatient costs were considered from the perspective 
of the public health care system. Hospital costs considered were ambulatory-, ward-, 
premedication-, drug- and administration costs. All costs referred to 2009. In medical 
practice, IVIG doses depend on a patient’s weight and age. Therefore separate analyses 
were conducted for children and adolescents vs. adults. RESULTS: Patients with 
replacement therapy were estimated to be 4192 (724 children and adolescents vs. 3450 
adults) for 2009. Patients with immunomodulation were estimated to be 1378 (244 
children and adolescents vs. 1134 adults) and patients with an allogeneic bone marrow 
transplantation were estimated at 172 (30 children and adolescents vs. 142 adults ). 
Mean annual costs for children and adolescents were c6283 with Privigen, c6292 with 
Kiovig, c6946 with Flebogamma and c6559 with Octagamocta. For adults estimations 
were c17,078 with Privigen, c17,103 with Kiovig, c18,095 with Flebogamma and 
c17,423 with Octagamocta. CONCLUSIONS: Direct medical costs for IVIGs were 
estimated to be c6.9 million for children and adolescents and c84.8 million for adult 
patients. Drug costs represented 94% of the total direct medical costs. In the context 
of limited health care resources, the choice for a certain IVIG treatment depends on 
individual patient characteristics and cost considerations.
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OBJECTIVES: To explore predictors of duloxetine initiation versus other standard of 
care (SOC) treatments for patients with diabetic peripheral neuropathic pain (DPNP) 
in the Veterans Affairs (VA) health system. Duloxetine was not on the VA national 
drug formulary. METHODS: The electronic medical records from January 2004 to 
December 2008 were requested from the Veterans Integrated Service Network 16 data 
warehouse. All patients selected initiated either duloxetine or SOC (tricyclic antide-
pressants [TCAs], venlafaxine, gabapentin, pregabalin) over the study period, with the 
ﬁ rst dispense date of the index agent as the index date. All patients must have at least 
1 prior DPNP diagnosis (ICD-9-CM: 250.6x or 357.2), but no prior depression (ICD-
9-CM: 296.2, 296.3, 300.4, 309.1, 311.0), ﬁ bromyalgia (ICD-9-CM: 729.1), or 
neuralgia (ICD-9-CM: 729.2) diagnosis. Logistic regressions were used to examine the 
predictors of initiating duloxetine versus SOC controlling for demographics, comor-
bidities, prior pain level, and prior SOC or opioid use. RESULTS: The analytical 
sample included 2675 (215 duloxetine and 2460 SOC) patients. Prior use of gabap-
entin (odds ratio [OR] = 13.66, 95% conﬁ dence interval [CI]: 9.70–19.24, TCAs (OR 
= 5.40, 95% CI: 3.73–7.82), or venlafaxine (OR = 3.67, 95% CI: 1.67–8.06) was 
strongly associated with duloxetine initiation. Patients comorbid with anxiety, cere-
brovascular disease, or substance abuse were 1.08 (95% CI: 1.40–3.08), 0.44 (95% 
CI: 1.01–2.07), and 1.11 (95% CI: 1.10–4.03) times more likely to initiate duloxetine, 
respectively. Prior opioid users were 1.47 (95% CI: 1.02–2.12) times as likely to initi-
ate duloxetine as those with no prior opioid use. Patients with self-reported severe 
pain were 1.66 (95% CI: 1.11–2.50) times as likely to initiate duloxetine as those with 
no reported pain. CONCLUSIONS: DPNP patients in the VA health care system who 
initiated duloxetine appeared to have prior SOC use, more comorbid conditions, prior 
substance abuse or opioid use, and higher pain level.
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OBJECTIVES: To summarise the state of knowledge of the economic impact of SLE 
and to gather information to implement a European study on costs of SLE care. 
METHODS: A systematic review of the literature was undertaken in the ECONLIT, 
EMBASE, Medline and EMBR databases for full papers relating to the objectives. Key 
words included SLE, cost, resource, economic, productivity, absenteeism, employment 
and work disability. Papers were excluded if they were not in English, French, Spanish, 
Italian or German language. RESULTS: Thirty relevant research papers (relating to 
13 different studies) were included. These studies were conducted in Canada, China, 
Germany, UK and US and used retrospective and prospective methods. Data were 
mainly obtained from the hospital care setting over a one-year study period. The main 
resources reported were physician and emergency visits, as well as inpatient hospital 
stays (of which SLE ﬂ ares and infections were the main causes). Annual direct costs 
(converted to December 2009 Euros) ranged from c2,879 (Canada) to c14,873 (US), 
with indirect costs of c1,214 (US/UK/Canada, friction method) to c45,668 (US, labour 
market activity method). Indirect costs accounted for at least 38% of the total costs 
when both market and non-market work was valued. Higher disease activity was 
reported as a predictor of higher direct and indirect costs. Greater damage, more ﬂ ares 
and nephritis were also found to predict higher direct costs whilst worse physical and/
or mental status predicted higher indirect costs. Only one study focussed on the cost 
of ﬂ ares. CONCLUSIONS: SLE is costly for the health care system and workplace. 
However, there is a lack of data on the cost of SLE ﬂ ares and little recent European 
data relating to the cost of SLE care. HGS/GSK funded.
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OBJECTIVES: To quantify the direct costs (hospitalizations and prescription drugs) 
of the caring strategies for the Inﬂ ammatory Bowel Disease (IBD). METHODS: All 
cases of the major types of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), 
occurred in Apulia between 2002 and 2006 were in the study. The patients were 
identiﬁ ed through a record linkage procedure among three different regional health 
databases. Multivariate Poisson regression accounting for over-dispersion was used to 
assess the average annual direct costs per person. Results were reported, separately 
for the two diseases, as Incidence Rate Ratios (IRR) with 95% conﬁ dence intervals. 
RESULTS: The cohort consisted of 2,700 cases of CD and 4902 cases of UC. We 
estimated the average annual costs per person in patients with CD to be equal to 7,153 
Euros for hospitalizations and to c2107 for prescription drugs. In patients with UC 
the average annual costs per person was of c6317 and c2277 for hospitalizations and 
prescription drugs, respectively. Surgical to medical DRGs ratio for both diseases was 
1:5 and the ATC codes relative to intestinal anti-inﬂ ammatory, proton pump inhibi-
tion, anti-inﬂ ammatory/anti-rheumatic and corticosteroids products, represented the 
40% of all prescriptions. Overall, the analyses showed, both for DC and CU, that the 
Charlson Comorbidity Index (CCI) was the only variable associated with the direct 
costs i.e. a signiﬁ cant increase in the costs (p-value < 0.0001) was found according to 
the severity of the CCI. In particular, it was noted that a worse clinical condition 
before disease onset (CCI before index date) was predictive of larger costs especially 
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in the case of UC. CONCLUSIONS: These preliminary results show that this innova-
tive cost estimation, obtained with this carefully controlled use of population wide 
databases, is a valuable alternative to traditional analyses obtained with ad hoc 
designed and less representative protocols.
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OBJECTIVES: Obesity is becoming to be treated like a worldwide epidemic. In Poland 
about 10.6% employees are obese. The objective of the studies was to estimate the 
indirect costs of obesity among Polish society. METHODS: Human Capital Approach 
method was used in costs quantifying. Data were collected from obese Polish employ-
ees. Work Productivity and Activity Impairment General Health questionnaire was 
used to estimate absenteeism and presenteeism in obese population. Indirect cost for 
general population was calculated on the basis of gross value added per employee in 
2008. Central Statistical Ofﬁ ce (GUS) data were used to identify obese epidemiology 
in employed population. Values are presented in Euro (exchange rate: 1 EUR = 4.10 
PLN). RESULTS: Data from 96 people were analyzed (mean age = 41.7 years, 34.4% 
men, average BMI = 34.2 kg/m2). Overall work impairment due to health problems 
in questioned population was estimated at 36.3%, with 11.8% of work time missed 
due to health problems. Taking into consideration that based on GUS data near 1.5 
million employees are obese total indirect costs of obesity in Poland in the year 2008 
were estimated at c10,5 billion representing 0.9% of gross domestic product. Absen-
teeism costs accounted for less than 1/3 of this costs (c3.4 billion) while pressenteism 
costs were estimated at amount of c7.0 billion. We didn’t ﬁ nd any correlation between 
BMI score and work impairment due to health problems (Pearson r = 0,15). 
CONCLUSIONS: Previously estimated direct medical costs of obesity (without obesity 
related diseases) covered by public payer were quantiﬁ ed at 4 million EUR in the year 
2008. We’ve found that indirect costs of lost productivity due to obesity are substantial 
to polish economy. However we conclude that not obesity itself but obesity related 
diseases generate most of indirect costs.
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OBJECTIVES: The objective of this review is to estimate the direct and indirect costs 
of Pompe disease. METHODS: Direct and indirect cots were estimated based on a 
questionnaire (consisting of 108 questions) measuring costs speciﬁ c for Pompe disease 
and a survey concerning the enzyme replacement therapy created for the research. The 
direct costs of Pompe disease were estimated from the patient`s social and the public 
health care system payer (National Health Fund) perspectives. While estimating indi-
rect costs human capital approach methodology was used taking into consideration 
absence from work due to the illness, lost time and salaries of the members of the 
family taking care of the patients. The analysis was done in a 2-year time span. 
RESULTS: In the research 80% of Pompe disease population were studied (N = 16). 
Indirect costs constituted 3% of the total cost (c17,959,67 per patient in the period 
of 2 years). The highest component of the amount was the cost of the income lost by 
the members of the families taking care of the patients; 96% of the total direct costs 
were the direct medical costs (c550,975.03 per patient in the period of 2 years). The 
main direct medical cost determinant is the enzyme therapy (c543,350.47)-constituting 
99% of the total direct medical costs. CONCLUSIONS: Providing patients with the 
prompt access to the enzyme replacement therapy result in lowering future indirect 
and direct costs: smaller number of patients taking disability pension, lower cost of 
medical equipment used by patients and higher productivity of patients able to work. 
Additionally there is a need to introduce an unusual and untypical approach in Health 
Technology Assessment.
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OBJECTIVES: To estimate the cost of care for CML in patients with resistance and/
or intolerance to imatinib from the public perspective in Mexico METHODS: Retro-
spective study of 208 patients diagnosed with CML, ≥18 years of age, treated with 
imatinib and having at least 12 months follow-up with ﬁ nal contact in the past three 
months, whom were attended at 6 tertiary level public hospitals in Mexico. Cost of 
care data captured includes drug costs (chemotherapy and imatinib), inpatient visits, 
toxicity treatment, and medical monitoring (labs studies, outpatient visits and other 
drugs costs). Costs are estimated on a monthly basis and are classiﬁ ed according to 
the presence of failure (toxicity or resistance to imatinib). Descriptive statistics on the 
use of resources are reported. RESULTS: At diagnosis of CML, 95% of patients were 
in chronic phase and 5% in accelerated phase. Fifty-ﬁ ve percent were female, with a 
mean age of 48.30. Deﬁ ning treatment failure as any imatinib dose adjustment, increas-
ing if resistance (lack of hematological and/or cytogenetic response) or reduction if 
intolerance (toxicity), 84.7% of patients failed initial treatment with imatinib. The 
median time to imatnib dose adjustment was 5.1 months. The average monthly cost of 
diagnosis and treatment prior to receiving imatinib was estimated US$2,210.54 ($2461–
$2808); the average monthly cost during treatment of imatinib and prior to failure was 
estimated US$2793 ($1612–$3125). The average monthly cost after failure increased to 
US$4706.18 ($3642–$5770), which represents an increment of 68.5% (t-test P < 0.001). 
The cost drivers of the increase are primarily: 1) inpatient visits, which increase from 
US$180 pre-failure to USD$367 post-failure, and 2) resources used in medical monitor-
ing and CML treatment, which increase from US$3678 pre-failure to US$4338 post-
failure per month. CONCLUSIONS: Once patients are resistant or intolerant to 
imatinib, their cost of treatment increases through additional demand for medical 
resources at Mexican public health care institutions.
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OBJECTIVES: To assess treatment costs per overall platelet response with 
romiplostim+concurrent treatment vs. placebo+concurrent treatment in chronic adult ITP, 
from a national payer perspective in Spain. METHODS: Platelet response was deﬁ ned as 
a platelet count of ≥50×109/L. Overall platelet response rates to romiplostim and placebo 
were used for the analysis and derived from two parallel clinical trials in splenectomized 
and non-splenectomized ITP patients [1]. All patients were allowed to enter on concurrent 
ITP medication (danazol, corticosteroids, azathioprine) and receive rescue medication (eg, 
intravenous immunoglogulins). Treatment costs were calculated over the 24-week clinical 
trial period and included intervention, rescue medication and management of bleeding-
related events. Costs were based on the 2009 national reimbursement list. Mean treatment 
cost per response was calculated for overall population, and for splenectomized and non-
splenectomized patients. RESULTS: Cost per response was substantially lower for romip-
lostim compared to placebo. Overall response rate was 83% for romiplostim and 7% for 
placebo (splenectomized patients 79% vs. 0%, non-splenectomized patients 88% vs. 14%, 
respectively). Mean treatment costs were c15,781 for romiplostim and c8,111 for placebo 
(splenectomized patients c15,436 vs. c10,263, non-splenectomized patients c16,125 vs. 
c5,958, respectively). Cost per response with romiplostim was c19,013 compared to 
c115,871 with placebo (splenectomized patients c19,539 vs. inﬁ nite cost/response, non-
splenectomized patients c18,324 vs. c42,557, respectively). The main cost-offsets were 
due to reduced immunoglobulin rescue use. CONCLUSIONS: Romiplostim represents an 
efﬁ cient use of health care resources in both splenectomized and non-splenectomized ITP 
patients for the Spanish health care system, leading to a signiﬁ cant improvement in manag-
ing a disease with a limited number of existing effective therapies. [1] Kuter et al. Lancet 
2008;371:395–403.
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OBJECTIVES: Chronic pain is gaining importance as a major cost factor in health 
care. To gather information about analgesic pharmacotherapy of patients with chronic 
pain and perform cost estimations to guide future cost-effectiveness research in the 
area. METHODS: Data from patients aged above 44 years suffering from any chronic 
condition and receiving regular analgesic pharmacotherapy (≥6 months) who attended 
health care facilities within the area of Badalona during 2008 were collected in a 
retrospective study. Morbidity proﬁ les were deﬁ ned according to treatment setting 
(pain unit, hospital), WHO analgesic stage (1–2 versus 3), and a raw cost model based 
on resource use and work absenteeism was applied. Patients attending the pain unit 
or the hospital were considered undertreated if they were on stage 1–2 analgesics. 
Multiple regression was used to compare costs between undertreated and non-under-
treated patients among those attending the pain unit or the hospital. RESULTS: Just 
410 out of 18,157 patients ascertained (2.3%) were on stage 3 analgesics. Direct 
health care costs were greater in patients on Step 3 analgesics (mean [SD]: 5,505.6 
[5,046.4] ) than in patients on Steps 1 and/or 2 analgesics (c2,407.4 [2,436.2]), but 
not indirect costs (c258.5 [1,578.4] vs. c279.5 [1,423.6], respectively). Of patients 
attended in the pain unit and the hospital, 2.3% and 20.1%, respectively, were con-
sidered undertreated. Regression analyses revealed even greater costs in the subgroup 
of undertreated patients. CONCLUSIONS: Conclusion: Stage 3 analgesics are barely 
used. Up to one-ﬁ fth of patients may be undertreated, and prompted greater costs 
than those judged as properly treated. Regression analyses did not clarify what propor-
tion of their cost excess was attributable to undertreatment.
